Septerna, Inc. (SEPN)
NASDAQ: SEPN · Real-Time Price · USD
26.30
-0.65 (-2.41%)
May 18, 2026, 4:00 PM EDT - Market closed
Septerna Employees
Septerna had 130 employees as of December 31, 2025. The number of employees increased by 55 or 73.33% compared to the previous year.
Employees
130
Change (1Y)
55
Growth (1Y)
73.33%
Revenue / Employee
$555,808
Profits / Employee
-$277,231
Market Cap
1.19B
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 130 | 55 | 73.33% |
| Dec 31, 2024 | 75 | - | - |
| Sep 30, 2024 | 73 | - | - |
| Jun 30, 2024 | 68 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| Fortrea Holdings | 14,000 |
| AbCellera Biologics | 562 |
| Zenas BioPharma | 167 |
| Olema Pharmaceuticals | 137 |
| MoonLake Immunotherapeutics | 130 |
| DBV Technologies | 117 |
| Inventiva | 77 |
| Savara | 70 |
SEPN News
- 6 days ago - Septerna Transcript: Bank of America Global Healthcare Conference 2026 - Transcripts
- 7 days ago - Septerna reports Q1 EPS (19c), consensus (27c) - TheFly
- 7 days ago - Septerna Highlights Business Progress and Reports First Quarter 2026 Financial Results - GlobeNewsWire
- 13 days ago - Septerna to Present at Bank of America Securities Health Care Conference - GlobeNewsWire
- 18 days ago - Septerna initiated with a Buy at Stifel - TheFly
- 5 weeks ago - Septerna doses first patients in SEP-479 trial - TheFly
- 5 weeks ago - Septerna Announces Initiation of Phase 1 Clinical Trial of SEP-479, an Oral Small Molecule PTH1R Agonist for the Treatment of Hypoparathyroidism - GlobeNewsWire
- 7 weeks ago - Septerna price target raised to $38 from $34 at JPMorgan - TheFly